Asset-manager Canary Capital filed an S-1 with the U.S. Securities and Exchange Commission on 17 July seeking approval for the Canary Staked INJ ETF, the first U.S. exchange-traded fund designed to hold and actively stake Injective’s native INJ tokens. The fund would track the price of the layer-1 blockchain’s asset while distributing staking rewards to shareholders, according to the filing posted on the SEC’s website. Canary said the ETF aims to lower technical barriers for investors by integrating on-chain staking—currently estimated to yield between 10% and 12% annually—into a regulated product that can be bought through traditional brokerages. “This ETF integrates staking into a regulated format, giving both institutions and individuals secure access to the new future of finance,” Injective co-founder Eric Chen said in a statement. The application continues Canary’s push to package higher-yield crypto assets in traditional wrappers. The firm has pending or recently submitted filings for staked funds tied to Solana, XRP, Hedera and other tokens, and last month established a Delaware statutory trust to underpin the Injective vehicle. Regulatory momentum around staking funds has quickened under the Trump administration’s more crypto-friendly SEC leadership. Earlier this month the agency allowed the REX-Osprey Solana Staking ETF to begin trading, and several asset managers, including Grayscale and 21Shares, are seeking permission to add staking to existing products. Injective, the 88th-largest digital asset by market value, traded around $13.84 on Thursday, up roughly 3.7% over 24 hours, according to CoinGecko data.